Journal Watch · Nature Biotechnology · 2026

Single-cell polygenic risk scores dissect cellular and molecular heterogeneity of complex human diseases.

Applied to these diseases, scPRS fine-maps causal cell types and cell-type-specific variants and genes, demonstrating its ability to bridge genetic risk with cell-specific biology. scPRS provides a unified framework for genetic risk prediction and mechanistic dissection of complex diseases, laying a methodological foundation for single-cell genetics.

Zhang S, Shu H, Zhou J et al.Nature Biotechnology3 min readPharma relevance 30/100

DOI: 10.1038/s41587-025-02725-6PMID: 40715455Study type: genomics / omics study

TL;DR

Applied to these diseases, scPRS fine-maps causal cell types and cell-type-specific variants and genes, demonstrating its ability to bridge genetic risk with cell-specific biology. scPRS provides a unified framework for genetic risk prediction and mechanistic dissection of complex diseases, laying a methodological foundation for single-cell genetics.

Key findings

  • Beyond risk prediction, scPRS prioritizes disease-critical cells and, when combined with a layered multiomic analysis, links risk variants to gene regulation in a cell-type-specific manner.
  • Applied to these diseases, scPRS fine-maps causal cell types and cell-type-specific variants and genes, demonstrating its ability to bridge genetic risk with cell-specific biology. scPRS provides a unified framework for genetic risk prediction and mechanistic dissection of complex diseases, laying a methodological foundation for single-cell genetics.

What they did

We introduce scPRS, a graph neural network-based framework that computes single-cell-resolved PRSs by integrating reference single-cell chromatin accessibility profiles. scPRS outperforms traditional PRS approaches in genetic risk prediction, as demonstrated across multiple diseases including type 2 diabetes, hypertrophic cardiomyopathy, Alzheimer disease and severe COVID-19.

Full abstract (original)

Background: Polygenic risk scores (PRSs) predict an individual's genetic risk for complex diseases, yet their utility in elucidating disease biology remains limited.

What they did: We introduce scPRS, a graph neural network-based framework that computes single-cell-resolved PRSs by integrating reference single-cell chromatin accessibility profiles. scPRS outperforms traditional PRS approaches in genetic risk prediction, as demonstrated across multiple diseases including type 2 diabetes, hypertrophic cardiomyopathy, Alzheimer disease and severe COVID-19.

Results & conclusions: Beyond risk prediction, scPRS prioritizes disease-critical cells and, when combined with a layered multiomic analysis, links risk variants to gene regulation in a cell-type-specific manner. Applied to these diseases, scPRS fine-maps causal cell types and cell-type-specific variants and genes, demonstrating its ability to bridge genetic risk with cell-specific biology. scPRS provides a unified framework for genetic risk prediction and mechanistic dissection of complex diseases, laying a methodological foundation for single-cell genetics.

Abstract © the authors / Nature Biotechnology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1038/s41587-025-02725-6 · PubMed 40715455.

Why it matters for pharma & biotech

  • Relevant to Biology & Life Sciences teams tracking Nature Biotechnology for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Nature Biotechnology study find?

Applied to these diseases, scPRS fine-maps causal cell types and cell-type-specific variants and genes, demonstrating its ability to bridge genetic risk with cell-specific biology. scPRS provides a unified framework for genetic risk prediction and mechanistic dissection of complex diseases, laying a methodological foundation for single-cell genetics.

What type of study is this?

It is a genomics / omics study, published in Nature Biotechnology in 2026. We introduce scPRS, a graph neural network-based framework that computes single-cell-resolved PRSs by integrating reference single-cell chromatin accessibility profiles.

Where can I read the original paper?

The original is at the publisher via DOI 10.1038/s41587-025-02725-6. PubMed ID: 40715455. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Zhang S, Shu H, Zhou J et al.. Single-cell polygenic risk scores dissect cellular and molecular heterogeneity of complex human diseases.. Nature Biotechnology (2026). DOI: 10.1038/s41587-025-02725-6.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/single-cell-polygenic-risk-scores-dissect-cellular-and-molecular-heterog-027256/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides